News
INCY
51.92
-0.82%
-0.43
Incyte To Buy Privately Held Escient Pharma
NASDAQ · 28m ago
Incyte Initiated at Neutral by Cantor Fitzgerald
Dow Jones · 32m ago
Cantor Fitzgerald Initiates Coverage On Incyte with Neutral Rating
Benzinga · 38m ago
Incyte to acquire immune-focused drug developer Escient
Healthcare M&A Incyte to acquire immune-focused drug developer Escient Pharmaceuticals. Escient is focused on developing small-molecule drugs for immune and neuro-immune disorders. The buyout is expected to conclude by Q3 2024. Incyte will pay $750M plus Escient's net cash for the company.
Seeking Alpha · 1h ago
Incyte to Buy Escient Pharmaceuticals for $750 Million
Incyte has struck a deal to buy clinical-stage drug discovery and development company Escient Pharmaceuticals for $750 million. Incyte says the acquisition complements its expanding R&D activities in inflammation and autoimmunity. The acquisition is slated to close by the third quarter.
Dow Jones · 1h ago
Incyte To Acquire Escient And Its Assets For $750M Plus Escient's Net Cash Remaining At The Close Of The Transaction, Subject To Customary Adjustments
Incyte to acquire Escient Pharmaceuticals for $750 million. Escient is developing drugs for systemic immune and neuro-immune disorders. Incyte says it will acquire the company's assets for the same amount. The deal is expected to close in the third quarter of 2024.
Benzinga · 1h ago
*Incyte to Acquire Escient for $750 Million Plus Net Cash Remaining at Close >INCY
Dow Jones · 1h ago
INCYTE CORP: WILL ACQUIRE ESCIENT AND ITS ASSETS FOR $750 MLN PLUS ESCIENT'S NET CASH REMAINING AT CLOSE OF TRANSACTION
Reuters · 1h ago
*Incyte Announces Acquisition Of Escient Pharmaceuticals And Its Pipeline Of First-in-Class Oral MRGPR Antagonists >INCY
Dow Jones · 1h ago
Top high growth investment ratio stocks from each sector - GS
Goldman Sachs analysts listed the top stocks in each sector with the highest growth investment ratio. Analysts said they forecast capex and R&D growth to slow from about 10% in 2023 to about 7% in 2024. Growth investment ratio is defined as a company's capex less depreciation plus R&d as a share of its cash flow.
Seeking Alpha · 16h ago
Weekly Report: what happened at INCY last week (0415-0419)?
Weekly Report · 1d ago
Goldman picks top capex and R&D stocks
Goldman Sachs expects capex and R&D growth to slow to 7% this year, down from 10% in 2023. Sales growth is the largest driver of capex growth in Goldman's model. The mega-cap tech stocks are committed to investing in AI. The top 10 firms with the largest capex spending are expected to be in the S&P 500.
Seeking Alpha · 1d ago
Top 10 most oversold S&P 500 stocks
Seeking Alpha · 3d ago
INCYTE CORP <INCY.O>: BMO CUTS TARGET PRICE TO $56 FROM $64
Reuters · 4d ago
CHINA MEDICAL SYSTEM - APPROVAL FROM PHARMACEUTICAL ADMINISTRATION BUREAU OF MACAU
Reuters · 6d ago
Certain Biotech Investors Get an Early Look at Results. Is That Fair? -- Heard on the Street
Biotech companies are increasingly turning to PIPEs, or private investments in public equities. In the first quarter, U.S. Biotechs raised a record $5.7 billion using the approach. Some investors say the PIPE boom is leaving out generalist investors. Some say the deals are a form of legal insider trading.
The Wall Street Journal · 04/15 09:30
Weekly Report: what happened at INCY last week (0408-0412)?
Weekly Report · 04/15 09:18
Press Release: Incyte to Report First Quarter Financial Results
Incyte to Report First Quarter Financial Results on Tuesday, April 30, 2024. Incyte's first quarter financial results conference call and webcast will be held at 8:00 a.m. ET. A replay of the conference call will be available for thirty days.
Dow Jones · 04/11 12:04
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 04/09 02:40
More
Webull provides a variety of real-time INCY stock news. You can receive the latest news about Incyte Corp through multiple platforms. This information may help you make smarter investment decisions.
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs.